Pharmaceuticals, Biotechnology & Life Sciences

Discover how AstraZeneca’s upcoming first‑half results will shape healthcare pricing, reimbursement, and operational strategy in 2024.

Argenx’s $2.2 billion cash acquisition of Forte Biosciences adds the promising anti‑CD122 antibody FB102 to its autoimmune portfolio, boosting growth, payer value, and market position.

Explore Swiss pharma’s steady gains: Roche’s oncology growth, Lonza’s manufacturing expansion, and strategic M&A amid patent cliffs.

West Pharmaceutical Services shines in income‑focused ETFs, delivering stable dividends and cutting‑edge drug delivery tech for biopharma.

Discover which pharma giants dominate the market by mastering patents, pipeline depth, and clinical proof—insights for investors seeking long‑term value.

West Pharmaceutical Services Q2 2026: modest sales growth, $210 M operating income, and a $112 M AbbVie sale boosting cash & future innovation.

Sanofi pulls back on its anti‑IL‑31 antibody, amlitelimab, amid fierce dermatology competition—redirecting cash toward high‑potential niche therapies.

EMA backs Enhertu + pertuzumab for HER2‑positive metastatic breast cancer, offering 85% ORR, 36‑month PFS and a manageable safety profile to reshape first‑line treatment.

Genmab/AbbVie’s phase‑3 EPCORE DLBCL‑1 study shows epcoritamab improves PFS and ORR, yet falls short of US OS approval—implications for patients, payers, and Genmab’s future strategy.

United Therapeutics Corp. reports July 2026 executive share trades—CEO’s 330k‑share trust purchase confirms leadership confidence and regulatory transparency.